Scientists Finally Found the Psychedelic Source of LSD
The fungus from which LSD was first synthesized has finally been observed and described by researchers who suspected a fuzz inside the seed coats of morning glory plants.
Now known as Periglandula clandestina, this fungal symbiote that coexists with morning glories was so difficult to find because it lives inside the plant as opposed to its Periglandula relatives which live on the outsides of plants and are more easily observable.
In the future, P. clandestine could lead to new and more powerful pharmaceuticals that treat migraines and neurodegenerative conditions.
In 1963, Swiss chemist Albert Hofmann discovered what gave morning glories psychoactive properties, the lysergic acid amides that would later lead him to (accidentally) create LSD.
Hofmann already knew about a mind-altering hallucinogen in morning glories that had been used in Mesoamerican religious rituals since ancient times. Seeing these chemicals in a plant was unexpected, since they are usually associated with fungi. The morning glory fungus eluded him. Finding it would prove to be a trip.
Morning glories (Convolvulaceae) are known for having symbiotic relationships with fungi that produce ergot alkaloids. These are the mycotoxins from which some hallucinogens, along with powerful medications for conditions such as dementia and migraines are derived. Many of the fungi that produce these substances belong to the family Clavicipitaceae.
While many species of morning glories have been found to contain ergot alkaloids, their fungal symbionts have not always been observed easily. Clavicipitaceae are often detected through DNA or their disappearance when a plant is treated with fungicide.
Researchers Corinne Hazel and Daniel Panaccione of West Virginia University knew of evidence for a psychotropic fungus in morning glories. The seed-borne fungus is a Clavicipitaceous genus known as Periglandula, and lives in symbiosis with the morning glory species Ipomoea tricolor, but had never been described further.
'The presence of ergot alkaloids in I. tricolor was associated with [genetic] sequences of an undescribed fungus of the family Clavicipitaceae,' Hazel and Panaccione said in a study recently published in Mycologia. 'Further evidence of a fungal symbiont of I. tricolor included suppression of ergot alkaloid synthesis through treatment with [a] fungicide.'
The researchers sought to isolate the fungus and sequence its genome so they could finally describe it. Plant tissues were magnified up to 200 times to search for visible signs of mycelium. Hyphae are the filaments in mycelium which branch out and connect networks of mushrooms underground and make up that dreaded white fuzz seen on moldy bread. Some of morning glory tissues were stained so the mycelium would be easier to identify, and other tissues were given nutrients to promote fungal growth.
Because Clavicipitaceae live in seeds, DNA from was also extracted from morning glory seed coats. Hazel knew she was onto something when she spotted white fuzz growing insides of sed coats and suspected fungi.
When scientists sequenced the genome of the fungus was sequenced, they found a previously undescribed species of Periglandula. Hazel named it Periglandula clandestina because of how it hides itself within the morning glory plant, which separates it from the other known Periglandula species that grow on the outside of the plant and are not as secretive. Ergot alkaloids were found throughout the plants. They are even present in the roots, where there was no evidence of P. clandestina DNA.
The most common alkaloid found in the plants was lysergic acid alpha-hydroxyethylamide (LAH). This alkaloid is one of the lysergic acid amides Hofman identified in his studies. LSD aside, the discovery of the fungus it is synthesized from could open opportunities for significant pharmaceutical discoveries in the future.
'Because P. clandestina produces exceptionally high quantities of ergot alkaloids, the genes in its ergot alkaloid biosynthesis pathway may be a resource for engineering model organisms to overproduce pharmaceutically relevant ergot alkaloids,' said Hazel and Panaccione.
The discovery that flowered from a suspicion about fuzz on a seed coat is almost as accidental as the discovery of a substance that will forever be associated with the undulating rainbows of '60s psychedelia, the Beatles' iconic 'Lucy in the Sky With Diamonds,' and even cult pop culture icons like Futurama's Hypnotoad.
Even Hoffman himself is quoted as saying, 'I did not choose LSD. LSD found and called me.'
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Geographic
3 days ago
- National Geographic
Will psychedelics ever live up to their hype?
Psychedelic drugs, like MDMA, have garnered promising results in treating a long list of mental health conditions. But some researchers say the studies have some key shortcomings. Photograph by Daria Kulkova, Getty Images The mind-expanding drugs may help heal many mental health conditions. But studies haven't actually proved that yet. In recent years, the conversation around psychedelic medicine has shifted from hushed discussions to headline news, with many media articles trumpeting positive scientific findings. Studies have found psychedelics effective for a wide range of mental health conditions, including depression, post-traumatic stress disorder, and substance abuse, and even physical conditions such as chronic pain. Results have been so promising that three states, Oregon, Colorado, and New Mexico, have created pathways for psychedelics to be legally administered there. And at least in part because of the positive research news, illegal use of the drugs—a category that includes psilocybin (the active ingredient in magic mushrooms), lysergic acid diethylamide (LSD), ayahuasca, and other compounds that alter consciousness—has risen across the United States. For example, psilocybin use in people over 30 increased by nearly 200 percent between 2019 and 2023, with many saying they took the drug to improve a mental health condition or chronic pain. Momentum is building towards a possible psychedelic drug approval by the U.S. Food and Drug Administration (FDA) in the next few years. Yet some in the field say the research continues to have significant problems that make broad conclusions about their benefit premature. Despite all the hype, 'we cannot conclude anything as of yet about the safety or efficacy of psychedelic therapy' for many of the conditions it's been touted to treat, says Michiel van Elk, a cognitive neuroscientist at Leiden University in the Netherlands, who coauthored an analysis in 2023 of the research's shortcomings. Some of the red flags took the spotlight last year, when the FDA rejected one of the most well-studied of the drugs, methylenedioxy-methamphetamine (MDMA), as a treatment for post-traumatic stress disorder. Even MDMA requires another large clinical trial to address lingering concerns, van Elk says. Some issues plaguing psychedelic research stem from the youthfulness of the field. Although scientists preliminarily studied the drugs during the 1950s and 60s, most of the research has happened in the past decade. But other hurdles are specific to experimenting with mind-altering substances. Here are three of the major concerns. 1. Psychedelic studies have been shockingly small. Studying these compounds is admittedly challenging. The drugs must be administered in person, generally in the presence of two trained facilitators who stay with each clinical trial participant for the six to ten hours the substance remains active. People also generally talk to therapists several times in the weeks before and after the experience. Plus, the medicine is time-consuming to get, due to restrictive government regulations. All told, running a single participant through a psychedelic study can cost tens of thousands of dollars, van Elk estimates. (Who will guide your psychedelic medicine trip?) To make studies affordable, most psychedelic research has included a small number of participants. One widely touted study finding benefits of psilocybin for major depression involved just 27 participants. Only 39 people took part a study documenting LSD's advantages for treating anxiety. Even the two studies submitted to the FDA in 2024 seeking approval for MDMA included 90 and 104 participants, respectively. By contrast, when the diabetes drug Ozempic was approved in 2017, its manufacturer submitted results in more than 4,000 people. In studies this small, a few individuals having unique experiences can skew the findings, especially if the people differ from the average to start. 'People who agree to these trials may not reflect the general population: They may be more desperate, more resistant of conventional treatments, more willing to try something wildly different from the norm,' says Frederick Barrett, a neuroscientist and director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine. Only larger studies can confirm positive results from these small trials. 'If you want to say anything meaningful, you need to increase sample sizes by hundreds of participants,' van Elk says. One way to bring up the numbers is to pool results. Researchers did this in 2024, combining nine clinical trials on psilocybin for depression, which together found the drug twice as effective as a placebo, the inert substance used for comparison in drug trials. But even this pooled analysis, while lending support to prior results, involved just 436 total participants. 2. People are bummed when they figure out that they didn't get the drug. The most reliable studies are 'double-blind,' where neither the person giving the medicine nor the person taking it knows whether they got the drug or the placebo. This helps keep people from incorrectly attributing health improvements to the medicine. But it's nearly impossible to keep study participants from the fact that they've taken a psychedelic when the room starts singing or their hands disappear before them. 'Psychedelic studies go through the motion, but it's functionally not blinded. Everybody figures it out,' says Balázs Szigeti, a clinical data scientist in the Translational Psychedelic Research program at the University of California, San Francisco, who studies this issue. People who don't get the drug seem to especially disappointed—more so than with other medications. 'Nobody wants to be in the placebo group,' Szigeti says. 'It's a great conversation when at cocktail parties you tell your friends you're going to be in a psychedelic drug trial. But imagine months later at the same social gathering when you have to tell them nothing happened.' This letdown may skew results, causing placebo-takers in psychedelic studies to underreport improvements. In a 2024 review, researchers found that people getting placebos in clinical trials testing the antidepressant escitalopram reported greater improvements in their depression levels than comparable studies for psychedelics. The wider gap between the psychedelic and placebo group artificially makes psychedelics look better, especially when they are compared to antidepressants, Szigeti says. In reality, the two treatments may be more evenly matched. Szigeti compared results from psychedelic and antidepressant studies without a placebo group, where everyone got an active treatment, and his unpublished data suggest they actually have similar effects. Of course, that may not be a bad thing. Antidepressant pills must be taken daily and come with side effects like weight gain and sexual disfunction. In comparison, one or two psychedelic sessions, which seem to convey lasting effects, could provide an appealing alternative for some patients. But such a finding would be far from the hype 'that psychedelics can cure depression,' Barrett notes. Scientists have been unable to find a placebo that does not tip off participants. They've tried a form of vitamin B that causes tingling and flushing, a cough medicine that can make people woozy, and even low doses of the psychedelic itself. But when people are asked during the clinical trial, most know they were not given the psychedelic. A more effective approach may be to randomize people earlier in the process so the placebo group never knows they could have gotten a psychedelic, Szigeti says. Studies could also be designed with a so-called cross-over design where everyone eventually gets the psychedelic, minimizing the disappointment of those who initially do not. 3. It's unclear how addictive some substances are. One of the biggest concerns raised by the FDA advisory committee assessing MDMA was the potential for abuse should the drug become legally available. Committee members complained that the company submitting the application, Lykos Therapeutics, had not asked study participants if they experienced euphoria or elation while on the drug—a sign some might seek to later abuse it. More than two million people in the U.S. illegally use MDMA, known on the street as Ecstasy or Molly—making it the fourth most common street drug after marijuana, cocaine, and methamphetamine. (Five recent scientific findings that change what we know about cannabis.) Psilocybin and LSD are less likely to be psychologically addictive than MDMA, Barrett says. In lab studies, animals exposed to an addictive drug like cocaine seek it out to the exclusion of food and water, but 'you have to bend over backwards' to get animals to take these psychedelics, he says. Still, the potential for abuse is rarely addressed in psychedelic research, even though critics think it always should be. 'Absence of data is not evidence of absence,' van Elk says. The potential for addiction is one reason drug companies are working to produce psychedelics that convey a health benefit without inducing the hallucinations or euphoria that might entice people to seek out these substances. (Scientists are creating psychedelics without the trips.) As the field of psychedelic science matures and seeks broader acceptance, including perhaps FDA approval of one or more of the drugs, a growing number of researchers are starting to take critiques of their work to heart. 'People are becoming aware that we potentially face a credibility crisis,' van Elk says, 'and that we need to do everything we can to make sure that we do the science according to the highest standards possible.'
Yahoo
17-07-2025
- Yahoo
RFK Jr. and other Trump officials embrace psychedelics after FDA setback
WASHINGTON (AP) — For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with depression, trauma and other hard-to-treat conditions. A presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' Health Secretary Robert F. Kennedy Jr. recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. And it comes as psychedelics are making inroads in deep red states like Texas, where former Trump cabinet secretary and ex-governor Rick Perry has thrown his full support behind the effort. The administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organization has pursued the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved.'' FDA may reconsider MDMA Under President Joe Biden, the FDA rejected MDMA as a treatment for post-traumatic stress disorder, citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first U.S. approval of a psychedelic for medical use. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new program promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. The U.S. Department of Health and Human Services and FDA also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. 'We didn't hear anything about that in the Biden administration' A spokesperson for HHS did not respond to a request for comment. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. A number of veterans lobbying for psychedelic access have already met with Trump's Secretary of Veterans Affairs, Doug Collins. 'What we're seeing so far is positive,' Collins told House lawmakers in May. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardize patients. "If Robert F. Kennedy Jr. and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.' Texas goes all-in on ibogaine research As officials in Washington weigh the future of psychedelics, some states are moving ahead with their own projects in hopes of nudging the federal government. Oregon and Colorado have legalized psychedelic therapy. And last month, Texas approved $50 million to study ibogaine, a potent psychedelic made from a shrub that's native to West Africa, as a treatment for opioid addiction, PTSD and other conditions. The research grant — the largest of its kind by any government — passed with support from the state's former GOP governor, Perry, and combat veterans, some who have traveled to clinics in Mexico that offer ibogaine. Ibogaine is on the U.S. government's ultra-restrictive list of illegal, Schedule 1 drugs, which also includes heroin. So advocates in Texas are hoping to build a national movement to ease restrictions on researching its use. 'Governmental systems move slowly and inefficiently,' said Bryan Hubbard of Americans for Ibogaine, a group formed with Perry. 'Sometimes you find yourself constrained in terms of the progress you can make from within.' Ibogaine is unique among psychedelics in both its purported benefits and risks. Small studies and anecdotal reports suggest the drug may be able to dramatically ease addiction and trauma. It was sold for medical use in France for several decades starting in the 1930s, but the drug can also cause dangerous irregular heart rhythms, which can be fatal if left untreated. Some veterans who have taken the drug say the risks can be managed and ibogaine's healing properties go far beyond antidepressants, mood stabilizers, counseling and other standard treatments. Marcus Capone struggled with anger, insomnia and mood swings after 13 years as a Navy Seal. In 2017, at the urging of his wife Amber, he agreed to try ibogaine as a last resort. He described his first ibogaine session as 'a complete purge of everything.' 'But afterward I felt the weight just completely off my shoulders,' he said. 'No more anxiety, no more depression, life made sense all of a sudden.' A nonprofit founded by the Capones, Veterans Exploring Treatment Solutions, or VETS, has helped over 1,000 veterans travel abroad to receive ibogaine and other psychedelics. But federal scientists have looked at the drug before — three decades ago, when the National Institute on Drug Abuse funded preliminary studies on using it as an addiction treatment. The research was discontinued after it identified 'cardiovascular toxicity." 'It would be dead in the water,' in terms of winning FDA approval, longtime NIDA director Nora Volkow said. But Volkow said her agency remains interested in psychedelics, including ibogaine, and is funding an American drugmaker that's working to develop a safer, synthetic version of the drug. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
USA Today
16-07-2025
- USA Today
Trump signs bill making tough sentences for fentanyl trafficking permanent
Nearly 73,000 people died from overdosing synthetic opioids such as fentanyl, according to the government. WASHINGTON – President Donald Trump signed a law that extends tougher prison sentences for fentanyl trafficking, surrounded by relatives of people who died from overdoses and lawmakers who approved the bill. 'Today we strike a righteous blow to the drug dealers, narcotic traffickers and criminal cartels,' Trump said. 'We take a historic step toward justice for every family touched by the fentanyl scourge.' The law places fentanyl on the Drug Enforcement Administration's list of most serious drugs with no accepted medical use and a high potential for abuse. The list includes drugs such as heroin, cocaine and LSD. Fentanyl has been temporarily assigned to the Schedule 1 category since 2018. The law makes the designation permanent. The law also makes permanent mandatory minimum penalties of five years in prison for trafficking 10 grams of fentanyl and 10 years for 100 grams. 'It doesn't sound like much, but it's a big deal," Trump said. The Department of Homeland Security seized 27,000 pounds of fentanyl and arrested 3,600 criminal suspects in 2024. More than 105,000 people nationwide died of drug overdoses in 2023, including nearly 73,000 from synthetic opioids such as fentanyl, according to the National Institute on Drug Abuse. The crackdown on fentanyl distribution is also at the heart of current U.S. trade disputes with China, Mexico and Canada. Trump imposed tariffs on those countries, citing the threat of cross-border fentanyl trafficking. 'We are delivering another defeat for the savage drug smugglers and criminals and the cartels," Trump said. Parents of several people who died after overdosing on fentanyl spoke at the event. Anne Fundner, whose 15-year-old son Weston died of an accidental fentanyl overdose in 2022, previously spoke at the Republican National Convention in Milwaukee last year. "It is a lifeline for families across America for keeping our families safe," Fundner said of the legislation. 'This is what we voted for, Mr. President." Gregory Swan, whose 24-year-old son Drew died of fentanyl poisoning, started a group known as Fentanyl Fathers, in which parents tell their story to high schools across America. 'His passing ruined, I thought, my life,' Swan said. 'There's despair and there's hopelessness. But we've been able to find some repose in going out and advocating.'
